ScholarLens Back to search
2021•Kidney International ReportsOpen access

POS-328 THE BURDEN OF HYPERKALEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE: A REPORT FROM THE DISCOVER CKD RETROSPECTIVE COHORT

Glen James, Juan Jesús Carrero, Supriya R. Kumar, Steven N. Fishbane, Eric T Wittbrodt, Eiichiro Kanda, Katarina Hedman, Naoki Kashihara, Mikhail Kosiborod, Mitja Lainščak, Carolyn S.P. Lam, Carol A. Pollock, Peter Stenvinkel, David Collins. Wheeler, Roberto Pecoits‐Filho

Open full text 3 citations

Abstract

Hyperkalemia (HK), defined as serum potassium (sK+) >5.0 mmol/L, is a potentially fatal condition most often observed in patients with chronic kidney disease (CKD), heart failure (HF) or diabetes and exacerbated by medications that inhibit the renin-angiotensin aldosterone system (RAASi). This real-world study describes characteristics of patients with and without HK in a large international observational study of patients with CKD.

About this research paper

What this paper is about

Hyperkalemia (HK), defined as serum potassium (sK+) >5.0 mmol/L, is a potentially fatal condition most often observed in patients with chronic kidney disease (CKD), heart failure (HF) or diabetes and exacerbated by medications that inhibit the renin-angiotensin aldosterone system (RAASi). This real-world study describes characteristics of patients with and without HK in a large international observational study of patients with CKD.

Why it matters

OpenAlex reports 3 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Hyperkalemia (HK), defined as serum potassium (sK+) >5.0 mmol/L, is a potentially fatal condition most often observed in patients with chronic kidney disease (CKD), heart failure (HF) or diabetes and exacerbated by medications that inhibit the renin-angiotensin aldosterone system (RAASi). This real-world study describes characteristics of patients with and without HK in a large international observational study of patients with CKD.

Key concepts: Hyperkalemia, Medicine, Kidney disease, Retrospective cohort study, Diabetes mellitus, Observational study, Cohort, Heart failure

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
POS-328 THE BURDEN OF HYPERKALEMIA IN PATIENTS WITH CHRONIC KIDNEY DISEASE: A REPORT FROM THE DISCOVER CKD RETROSPECTIVE COHORT — Research Paper | ScholarLens